Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yixiang Zhu

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|January 22, 2021
[Clinical Features of EGFR Mutation Negative in Patients 
with Non-small Cell Lung Cancer and Brain Metastases]Yixiang Zhu, Ye Zhang
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|July 28, 2022
[Current Progress and Future Developments of Antibody Drug Conjugates 
in Lung Cancer]Yixiang Zhu, Zhijie Wang
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 21, 2016
[Treatment of Advanced Squamous Cell Lung Cancer]Yixiang Zhu, Puyuan Xing, Junling Li
Thoracic Cancer|July 8, 2016
Exploration of optimal time for initiating adjuvant chemotherapy after surgical resection: A retrospective study in Chinese patients with stage IIIA non-small cell lung cancer in a single centerYixiang Zhu, Xiaoyu Zhai, Sipeng Chen, et al.
Frontiers in Immunology|February 27, 2026
Pathological complete response in esophageal squamous cell carcinoma complicated by malignant fistula via neoadjuvant immunotherapy, chemoradiotherapy, and nutritional support: a case reportNanxi Li, Mei Lan, Wenxiu Yao, et al.
European Journal of Pharmacology|June 15, 2017
Fumigaclavine C exhibits anti-inflammatory effects by suppressing high mobility group box protein 1 relocation and releaseWanguo Yu, Zhenghua Pan, Yixiang Zhu, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 5, 2019
[Review on Treatment Modalities for Resectable IIIa/N2 Non-small Cell Lung Cancer]Ziyi Xu, Puyuan Xing, Di Ma, et al.
Bioorganic & Medicinal Chemistry|October 1, 2025
Identification of a novel Aurora B inhibitor using the AI-driven drug screening and docking-based traditional screeningJiayuan Ye, Nan Chen, Yixiang Zhu, et al.
Journal of Cancer|October 9, 2020
Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimenXuezhi Hao, Yixiang Zhu, Yuxin Mu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 28, 2025
Clinical Features, Molecular Biology, and the Metastatic Microenvironment in Lung Cancer Brain Metastases: Implications for Treatment DecisionsYixiang Zhu, Danming He, Zan Hou, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|January 22, 2021
[Clinical Features of EGFR Mutation Negative in Patients 
with Non-small Cell Lung Cancer and Brain Metastases]Yixiang Zhu, Ye Zhang
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|July 28, 2022
[Current Progress and Future Developments of Antibody Drug Conjugates 
in Lung Cancer]Yixiang Zhu, Zhijie Wang
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 21, 2016
[Treatment of Advanced Squamous Cell Lung Cancer]Yixiang Zhu, Puyuan Xing, Junling Li
Thoracic Cancer|July 8, 2016
Exploration of optimal time for initiating adjuvant chemotherapy after surgical resection: A retrospective study in Chinese patients with stage IIIA non-small cell lung cancer in a single centerYixiang Zhu, Xiaoyu Zhai, Sipeng Chen, et al.
Frontiers in Immunology|February 27, 2026
Pathological complete response in esophageal squamous cell carcinoma complicated by malignant fistula via neoadjuvant immunotherapy, chemoradiotherapy, and nutritional support: a case reportNanxi Li, Mei Lan, Wenxiu Yao, et al.
European Journal of Pharmacology|June 15, 2017
Fumigaclavine C exhibits anti-inflammatory effects by suppressing high mobility group box protein 1 relocation and releaseWanguo Yu, Zhenghua Pan, Yixiang Zhu, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 5, 2019
[Review on Treatment Modalities for Resectable IIIa/N2 Non-small Cell Lung Cancer]Ziyi Xu, Puyuan Xing, Di Ma, et al.
Bioorganic & Medicinal Chemistry|October 1, 2025
Identification of a novel Aurora B inhibitor using the AI-driven drug screening and docking-based traditional screeningJiayuan Ye, Nan Chen, Yixiang Zhu, et al.
Journal of Cancer|October 9, 2020
Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimenXuezhi Hao, Yixiang Zhu, Yuxin Mu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 28, 2025
Clinical Features, Molecular Biology, and the Metastatic Microenvironment in Lung Cancer Brain Metastases: Implications for Treatment DecisionsYixiang Zhu, Danming He, Zan Hou, et al.
Pageof 9